Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler

Piper Sandler analyst Biren Amin raised the firm’s price target on Overweight-rated Kymera Therapeutics (KYMR) to $140 from $125 after transfer in analyst coverage. The firm believes Kymera is positioned to be a category leader in oral protein degraders, with early clinical data from its lead STAT6 degrader program supporting the thesis that TPD can deliver biologic-like pathway suppression in a convenient and scalable oral formulation. Collectively, Piper thinks Kymera’s combination of first-mover advantage in immunology degraders, oral differentiation versus biologics, and expanding clinical proof supports an attractive risk-reward profile at current levels.